Thursday 18 June 2026

The Pharma Letter Podcast — Episode 14 — A vaccine for Alzheimer's?

Biotechnology
Simon Wentworth
6 June 2022
episode14-big


More on this story...

Biotechnology
Encouraging early results in Alzheimer's for Prothena
26 July 2021
Biotechnology
Prothena pens $1.2 billion deal with Novo Nordisk
12 July 2021
Biotechnology
Roche and Prothena move forward with PD drug prasinezumab
22 October 2020
Biotechnology
Roche's 10-year Alzheimer's study yields depressingly familiar result
16 June 2022


Company News Directory



Companies featured in this story

More ones to watch >




Today's issue

Sanofi’s Sarclisa SC wins MHRA backing
Biotechnology
Sanofi’s Sarclisa SC wins MHRA backing
18 June 2026
Pharmaceutical
FDA drug approvals rebound above decade average in 2025, says GlobalData
18 June 2026
Pharmaceutical
Curium court decision advances therapy plans for GEP-NETs
18 June 2026
Biotechnology
FDA accepts Roche’s sBLA for Lunsumio and Polivy combo
18 June 2026
Pharmaceutical
J-Pharma and Uniphar advance nanvuranlat into global Phase III trial
18 June 2026
Biosimilars
Samsung Bioepis and Organon expand commercialization of Pyzchiva
18 June 2026
Generics
First generic Xofluza clears US FDA ahead of flu season
18 June 2026


Company Spotlight

Edgewise Therapeutics
A Boulder, Colorado-based biotech that has sharpened its focus entirely on cardiovascular disease after divesting its muscular dystrophy franchise to Servier, with oral cardiac sarcomere modulator EDG-7500 now its singular Phase III-bound bet in hypertrophic cardiomyopathy.


More Features in Biotechnology

Sanofi’s Sarclisa SC wins MHRA backing
18 June 2026
FDA accepts Roche’s sBLA for Lunsumio and Polivy combo
18 June 2026
Biogen expands immunology pipeline with RayThera buy
18 June 2026
Triveni Bio raises $65 million to advance atopic dermatitis bispecific
18 June 2026


Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze